Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Lymphoma Myeloma. 2009 Aug;9(4):307-10. doi: 10.3816/CLM.2009.n.060.

Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens.

Author information

1
James P. Wilmot Cancer Center, University of Rochester, Rochester, NY 14642, USA.

Abstract

Burkitt lymphoma is a highly curable disorder when treated with modern intensive chemotherapy regimens. The majority of adult patients with Burkitt lymphoma in the United States are over age 40 years. Older patients have historically been underrepresented in published clinical trials of modern intensive therapy, and the outcome of these patients has not been systematically reported. We therefore obtained and analyzed primary data from 14 Burkitt lymphoma treatment series and confirmed that older patients (age > 40 years) are underrepresented in the literature. Historically inferior outcomes of this age subgroup have improved substantially over time. We conclude that (1) modern intensive chemotherapy regimens should remain the standard of care for patients > age 40 with Burkitt lymphoma; (2) selected patients > age 40 now have highly favorable outcomes; and (3) future studies should include formal analysis of this subgroup of patients.

PMID:
19717381
PMCID:
PMC2909640
DOI:
10.3816/CLM.2009.n.060
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center